{"related:TVKDlrLb4cAJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5":[{"title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/nejmoa1712126","authors":["RJ Motzer","RJ Motzer NM Tannir","RJ Motzer NM Tannir DF McDermott…"],"year":2018,"numCitations":1247,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa1712126","citationUrl":"http://scholar.google.com/scholar?cites=13898631485117911629&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:TVKDlrLb4cAJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=13898631485117911629&hl=en&as_sdt=0,5","publication":"Mass Medical Soc","p":1,"exp":1596898396013},{"title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1816714","authors":["BI Rini","BI Rini ER Plimack","BI Rini ER Plimack V Stus","BI Rini ER Plimack V Stus R Gafanov…"],"year":2019,"numCitations":545,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa1816714","citationUrl":"http://scholar.google.com/scholar?cites=14370914940926626173&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:fQlJl_--b8cJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=14370914940926626173&hl=en&as_sdt=0,5","publication":"Mass Medical Soc"},{"title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1816047","authors":["RJ Motzer","RJ Motzer K Penkov","RJ Motzer K Penkov J Haanen","RJ Motzer K Penkov J Haanen B Rini…"],"year":2019,"numCitations":502,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa1816047","citationUrl":"http://scholar.google.com/scholar?cites=1882792696390332365&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:za8LXvsFIRoJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=1882792696390332365&hl=en&as_sdt=0,5","publication":"Mass Medical Soc"},{"title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/nejmoa1510665","authors":["RJ Motzer","RJ Motzer B Escudier","RJ Motzer B Escudier DF McDermott…"],"year":2015,"numCitations":3441,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa1510665","citationUrl":"http://scholar.google.com/scholar?cites=13492037867285985225&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:yTez1_RYPbsJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=13492037867285985225&hl=en&as_sdt=0,5","publication":"Mass Medical Soc"},{"title":"Изменение позиций иммунотерапии при распространенном раке почки: ниволумаб в комбинации с ипилимумабом в 1-й линии лечения","url":"https://cyberleninka.ru/article/n/izmenenie-pozitsiy-immunoterapii-pri-rasprostranennom-rake-pochki-nivolumab-v-kombinatsii-s-ipilimumabom-v-1-y-linii-lecheniya","authors":["ВБ Матвеев","ВБ Матвеев МИ Волкова","ВБ Матвеев МИ Волкова АС Ольшанская"],"year":2019,"numCitations":0,"pdf":"https://cyberleninka.ru/article/n/izmenenie-pozitsiy-immunoterapii-pri-rasprostranennom-rake-pochki-nivolumab-v-kombinatsii-s-ipilimumabom-v-1-y-linii-lecheniya","relatedUrl":"http://scholar.google.com/scholar?q=related:7KuOVGY_BUUJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=4973451072238431212&hl=en&as_sdt=0,5","publication":"cyberleninka.ru"},{"title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 …","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5455807/","authors":["TK Choueiri","TK Choueiri S Halabi","TK Choueiri S Halabi BL Sanford","TK Choueiri S Halabi BL Sanford O Hahn…"],"year":2017,"numCitations":386,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5455807/","citationUrl":"http://scholar.google.com/scholar?cites=5181895643400921433&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:WWEOAKLK6UcJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=5181895643400921433&hl=en&as_sdt=0,5","publication":"ncbi.nlm.nih.gov"},{"title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","url":"https://www.nature.com/articles/s41591-018-0053-3?sf191006923=1","authors":["DF McDermott","DF McDermott MA Huseni","DF McDermott MA Huseni MB Atkins","DF McDermott MA Huseni MB Atkins RJ Motzer…"],"year":2018,"numCitations":270,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6721896/","citationUrl":"http://scholar.google.com/scholar?cites=14003279356171476270&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:Ll0pw2GkVcIJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=14003279356171476270&hl=en&as_sdt=0,5","publication":"nature.com"},{"title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1803675","authors":["A Méjean","A Méjean A Ravaud","A Méjean A Ravaud S Thezenas…"],"year":2018,"numCitations":332,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa1803675","citationUrl":"http://scholar.google.com/scholar?cites=2759106540828352675&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:o-CHz8dQSiYJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=2759106540828352675&hl=en&as_sdt=0,5","publication":"Mass Medical Soc"},{"title":"IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC)","url":"https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.6_suppl.578","authors":["RJ Motzer","RJ Motzer T Powles","RJ Motzer T Powles MB Atkins","RJ Motzer T Powles MB Atkins B Escudier…"],"year":2018,"numCitations":165,"citationUrl":"http://scholar.google.com/scholar?cites=1771464359342537550&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:Tnvg_nKBlRgJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","publication":"ascopubs.org"},{"title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase …","url":"https://www.sciencedirect.com/science/article/pii/S0140673619307238","authors":["BI Rini","BI Rini T Powles","BI Rini T Powles MB Atkins","BI Rini T Powles MB Atkins B Escudier…"],"year":2019,"numCitations":181,"pdf":"https://researchers.mq.edu.au/en/publications/atezolizumab-plus-bevacizumab-versus-sunitinib-in-patients-with-p","citationUrl":"http://scholar.google.com/scholar?cites=16381744679535091864&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:mKDV6P2lV-MJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=16381744679535091864&hl=en&as_sdt=0,5","publication":"Elsevier"}]}